Mindset Pharma Inc. announced that through its discovery work, it has identified three additional families of highly novel, non-tryptamine, next-generation psychedelic compounds. Mindset's ambition since its formation has been to lead the medical psychedelic space in drug discovery by pushing the boundaries of known psychedelic drugs to create the broadest portfolio of varied and differentiated drug candidates. While much of the industry focus has been on classic psychedelic drugs, Mindset has purposefully expanded its discovery efforts beyond the tryptamine drug class into new, innovative chemical structures in order to develop superior neuropsychiatric medications.

Using a fragment-based drug discovery method combined with a highly focused medicinal chemistry strategy, Mindset's scientists designed and developed three new, chemically distinct, small molecule non-tryptamine scaffolds, Families 6, 7 and 8. Mindset has filed provisional patent applications on these families, with favorable FTO searches. Approximately forty novel drug-like lead compounds were synthesized and evaluated in in-vitro hydroxy tryptamine (5-HT) subtype receptors and in in-vitro absorption, distribution, metabolism, and excretion studies. To date, pre-clinical screening has shown significantly enhanced receptor functional potency and selectivity.

In addition, some of the new compounds have the potential for greater central nervous system penetration, oral activity and efficacy.